^
Association details:
Biomarker:No biomarker
Cancer:Hodgkin Lymphoma
Drug:cyclophosphamide (Alkylating agent)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
11/20/2023
Excerpt:
Cyclophosphamide Injection is an alkylating drug indicated for treatment of adult and pediatric patients with:• Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma